XXII on Monday announced it had signed a binding agreement with its senior secured lender to eliminate its senior secured debt through potential debt-for-equity exchanges. Additionally, it has ...

) has been revised to $9.18 / share. This is an increase of 28.57% from the prior estimate of $7.14 dated November 14, 2025. The price target is an average of many targets provided by analysts. The ...

View 22nd Century Group, Inc. XXII stock quote prices, financial information, real-time forecasts, and company news from CNN.

Biotech company 22nd Century Group (NASDAQ:XXII) must be smiling today after a recent U.S. Food and Drug Administration (FDA) designation has investors celebrating. Indeed, news broke today that the ...

22nd Century Group Inc (NASDAQ:XXII) reported a net loss of $72.72 million in Q3 2023, a significant increase from the $13.1 million loss in the same period last year. The company's VLN footprint ...